Matches 1 - 50 out of 163 1 2 3 4 >
Match Document Document Title
7388002 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases  
Compounds represented by the formula: A is (CH 2 ) n R 2 , —CH═CH 2 , CH 2 —CH═CH 2 , O(CH 2 ) n R 2 , CH(OH)CH 3 , CH(OH)CH 2 OH, CH 2 —CH(OH)CH 3 , CH 2 CH(OH)CH 2 OH, or...
7342021 Phosphodiesterase 4 inhibitors  
PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R 1 and R 2 are as defined herein.
7332486 Phosphodiesterase 4 inhibitors  
PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R 1 and R 2 are as defined herein.
7319101 COMT inhibitors for the treatment of depression and impaired cognition  
The present invention relates to compounds of formula I wherein R 1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the...
7317018 Anti-inflammatory medicament  
The use of adenosine-5′-triphosphate-2′,3′-dialdehyde (oATP) as a medicament useful for the treatment of inflammatory conditions is disclosed.
7279483 Famciclovir monohydrate  
Famciclovir monohydrate and its pharmaceutical use.
7279482 Heterocyclic compound based on N6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds  
Heterocyclic derivatives based on N 6 -substituted adenine of, e.g.,a formula: wherein R2 is hydrogen, R6 is R6′-X, X is —NH—, and R6′ is substituted phenyl or substituted benzyl. The...
7273864 Compositions and methods for inducing osteogenesis  
The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage, using compounds of the following formula: ...
7270804 Use of one or several substances selected from the group of pyrimidines and purines in cosmetic preparations for tanning the skin  
Use of one or more substances selected from the group of pyrimidines and purines for the preparation of cosmetic or dermatological preparations for boosting natural skin tanning and/or for...
7265111 Adenosine analogues and their use as pharmaceutical agents  
The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are independently 0, 1, 2, or 3, provided...
7256196 Purine cytokine inhibitors  
The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian...
7253175 Method for treating athlete's foot  
A method of treating a patient having a fungal infection comprises administering an effective fungal infection treatment amount of an antiviral agent, such as valacyclovir, to eliminate the...
7253154 Substituted thiazolopyrimidines as xanthine oxidase inhibitors  
The invention relates to compounds of the following formula (I) or their salts: in which R 1 represents OR 4 or others, in which R 4 is an alkyl group having 1-8 carbon atoms which may have...
7238700 A2B adenosine receptor antagonists  
Disclosed are novel A 2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R 1 is optionally substituted alkyl or a group —Y-Z, in which Y is...
7220757 Compositions and methods for topical administration of 2-NH-heteroarylimidazoles  
Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.
7220748 Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidine for treating of urinary incontinence  
4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)p yrimidine or a salt thereof is useful for the treatment of urinary incontinence.
7217716 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists  
Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain
7217702 Selective antagonists of A2A adenosine receptors  
Selective antagonists of A 2A adenosine receptors like those of formula I are provided, wherein Y forms a ring. The novel A 2A blockers are useful for the treatment of Parkinsons disease and...
7214665 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof  
The invention provides compounds having the following general formula (I): wherein X, R 1 , R 2 , R 7 and Z are as described here.
7196093 Reversible inhibitors of SAH hydrolase and uses thereof  
1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an...
7189730 A2A adenosine receptor antagonists  
Disclosed are novel A 2A adenosine receptor antagonists of the formula: wherein: R 1 is optionally substituted aryl or optionally substituted heteroaryl; R 2 is optionally substituted...
7183268 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents  
Compounds which are active against viruses have the following Formulas: wherein B is 2-aminopurine-9-yl, which may be unsubstituted or substituted in the 6 position with NHR 1 , OR 2 , or...
7157449 Medicament for the treatment of diseases caused by parasitic protozoa  
The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of...
7138401 2-aminopurine analogs having HSP90-inhibiting activity  
2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated...
7129239 Purine compounds and uses thereof  
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. ...
7087589 Methanocarba cycloakyl nucleoside analogues  
The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of...
7053097 Inhibitors of glycogen synthase 3 kinase  
Compounds of formula 1: wherein R 1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0–3 substituents selected from lower alkyl, halo, hydroxy,...
RE39112 Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes  
The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action. A purine...
7041667 CCR5 modulators  
Compounds of Formula 1 [R egion α]—[R egion β]—[R egion γ]—[R egion δ] (1)
6969720 Biaryl substituted purine derivatives as potent antiproliferative agents  
The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of...
6936602 Benzazepine derivatives, process for the preparation of the same and uses thereof  
Compounds of the general formula (I): or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R 1 is a 5- to 6-membered...
6887880 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof  
The present invention relates to derivatives and analogues of adenine of the formula: wherein L, A, Y and Z are those defined herein. Compounds of the present invention are useful in...
6841549 Condensed imidazole compounds and a therapeutic agent for diabetes mellitus  
The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is,...
6803371 Purine inhibitors of protein kinases, G proteins and polymerases  
The present invention relates to 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present...
6794390 Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha  
A compound having the formula: wherein: R 1 is —X—R 1 ′; in which R 1 ′ is lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl, or...
6790841 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents  
Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of...
6784174 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease  
This invention concerns a bicyclic compound of Formula (I), wherein: G is N, CH or C(CN); ring X is a 5- or 6-membered fused heteroaryl ring which contains 1, 2, or 3 heteroatoms selected from...
6784166 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication.  
The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols...
6767906 2-amino-6-anilino-purines and their use as medicaments  
This application discloses 2-amino-6-anilino-purine derivatives of the formula I in which q is 1-5, and R 1 is α) —S(═O) k —NR 6 R 7 , in which k is 1 or 2, wherein under the proviso...
6734187 Purine derivatives and medicaments comprising the same as active ingredient  
Purine derivatives represented by the following formula and salts thereof: wherein R 1 represents a C 1 -C 4 alkyl group or difluoromethyl group; R 2 represents tetrahydrofuranyl group, a C 1...
6703395 Cyclin dependent kinase inhibitor  
The present invention is based on the method of treating a patient suffering from leukemia comprising administering a therapeutically effective amount of the compound...
6696454 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation  
This invention provides a method for the treatment of a subject in need of treatment for osteoarthritis comprising administering to said subject an amount of an inhibitor of spermidine biosynthesis...
6642231 6,9-disubstituted 2-&lsqb trans-(4-aminocyclohexyl)amino&rsqb purines  
The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also...
6641843 Pharmaceutical compositions  
The present invention relates to pharmaceutical compostions of (1S,4R)-cis-4-[2-amino-6-cyclopropylamino}-9H-purin-9-yl]-2- cyclopentene-1-methanol (1592U89).
6630477 Therapeutic nucleoside compound  
The present invention relates to (1R,4S)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol and its use in medical therapy for the treatment of hepatitis B infection.
6627633 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents  
The compounds of the present invention are 2,6,9-trisubstituted purine inhibitors of cyclin/cdk complexes. The compounds also are potent inhibitors of human cellular proliferation. As such, the...
6605619 Nitroxides as protectors against oxidatives stress  
The instant invention is directed to the use of a biologically compatible composition, containing an effective amount of a metal-independent nitroxide compound which is preferably represented by...
6589950 Purine derivatives inhibitors of tyrosine protein kinase SYK  
Disclosed are compounds of the formula in free or salt form, wherein X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification, their preparation and their use as pharmaceuticals,...
6559148 Use of P2Y purinoreceptor antagonist for the treatment of ischemia reperfusion  
Use of compounds modulating P2 purinoceptors, in particular antagonists such as Basilen Blue E-3G (Reactive Blue 2), for the prevention of the damages due to global cerebral ischemia and...
6541482 Carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines  
The present invention relates to compounds of the formula wherein X is N 3 , NH 2 , NHR, N(R) 2 , CN, SH, SR, or OR 1 ; R is C 1 -C 4 alkyl or (CH 2 ) n —φ; n is an integer 0, 1, 2, 3 or 4;...
Matches 1 - 50 out of 163 1 2 3 4 >